Morphosys

Summary
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

History

The Company was founded in 1992. In 1999, MorphoSys listed on the Frankfurt Stock Exchange under the ticker symbol "MOR".

In 2004, MorphoSys and Novartis entered into a strategic partnership for the research and development of biopharmaceuticals, which was expanded in 2007. Additional discovery partnerships included: Bayer , Roche , Centocor , Schering AG and Pfizer .

In 2008, the company’s first proprietary antibody MOR103 entered clinical development. Following the publication of promising results in rheumatoid arthritis, MorphoSys signed a license agreement with GlaxoSmithKline for otilimab. In 2019, GlaxoSmithKline initiated a phase 3 clinical development program with otilimab .In 2010, MorphoSys signed a license agreement with Xencor Inc. for MOR208 .In July 2017, the first of MorphoSys’ platform drugs received US marketing approval. Guselkumab , which was developed and is being commercialized by Janssen Biotech a subsidiary of Johnson & Johnson, was first approved for the treatment of moderate-to-severe plaque psoriasis in the United States, the European Union and Canada.In April 2018, following a US initial public offering in which the company raised $239 million, American depositary shares of MorphoSys began trading on the Nasdaq stock exchange, also under the symbol "MOR."In 2018, the company established a wholly owned US subsidiary, MorphoSys US Inc..

In December 2019, based on positive clinical trial results, the company submitted a Biologics License Application to the FDA for tafasitamab in combination with lenalidomide for the treatment of relapsed/refractory diffuse large B-cell lymphoma. The submission was accepted for filing in February 2020, and a decision on the filing is expected in August 2020.In January 2020, MorphoSys and Incyte Corporation signed a collaboration and license agreement for the global development and commercialization of tafasitamab. On March 3, 2020, the agreement received antitrust clearance and thus became effective.In March 2020, MorphoSys announced that the FDA had accepted the Biologics License Application for filing and granted priority review for tafasitamab, setting a Prescription Drug User Fee Act goal date of August 30, 2020.On July 31, 2020, Monjuvi was approved by the U.S. FDA in combination with lenalidomide for the medical treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant .


Mission
Our mission is to discover, develop and commercialize innovative therapeutic proteins to combat previously untreatable diseases.

Vision
Our vision is to be a leader in the discovery and development of novel biotherapeutic products that have the potential to dramatically improve patients’ lives.

Key Team

Mr. Thomas Biegi (VP & Head of Corp. Communications)

Mr. Klaus De Wall (Head of Accounting & Tax)

Dr. Anja Pomrehn (Sr. VP & Head of Investor Relations)

Dr. Margit Urban (Head of Discovery Alliances & Technologies)

Ms. Lara Smith Weber (Head of Controlling, Corp. Fin. & Corp. Devel.)

Ms. Charlotte Lohmann (Sr. VP of Legal, Compliance & IP and Gen. Counsel)

Ms. Maria Castresana (Sr. VP & Global Head of HR)


Recognition and Awards
MorphoSys has been awarded numerous awards, including the German Creativity Award in 2010, the Innovation Prize from the German Ministry of Economics and Technology in 2011, and the European BioBusiness Award in 2018.

References
Morphosys
Leadership team

Dr. Marlies Sproll (Special Adviser to the Chief Exec. Officer)

Dr. Jean-Paul Kress M.D. (Chairman of Management Board, MD & CEO)

Mr. Sung H. Lee (CFO & Member of Management Board)

Products/ Services
Biotechnology, Health Care, Health Diagnostics, Medical
Number of Employees
500 - 1000
Headquarters
Planegg, Bayern, Germany
Established
1992
Company Registration
SEC CIK number: 0001340243
Revenue
100M - 500M
Traded as
MOR
Social Media
Sun Mar 03 2024
About

businessabc offers a global business, SMEs wiki directory blockchain, NFTs, AI powered marketplace for businesses worldwide.

Follow Us
Produced by
In collaboration with
Logo

Copyright 2023 © businessabc powered by ztudium